Biblio
Graft-versus-host-disease prophylaxis with ATG or PTCY in patients with lymphoproliferative disorders undergoing reduced intensity conditioning regimen HCT from one antigen mismatched unrelated donor. Bone Marrow Transplant. 2024.
The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan. Clin Lymphoma Myeloma Leuk. 2024.
Nutritional strategies to improve VRE control. Transplant Cell Ther. 2024.
CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation. Bone Marrow Transplant. 2023.
. Exosomes in Chronic Myeloid Leukemia: Are We Reading a New Reliable Message?. Acta Haematol. 2020:1-2.
. Minimal residual disease monitoring in acute myeloid leukaemia: are we ready to move from bone marrow to peripheral blood?. Br J Haematol. 2020.
. Second primary malignancy in myelofibrosis patients treated with ruxolitinib. Br J Haematol. 2020.
Busulfan or thiotepa based conditioning in myelofibrosis: a phase II multicenter randomized study from the GITMO group. Biol Blood Marrow Transplant. 2018.
Zebrafish disease models in hematology: Highlights on biological and translational impact. Biochim Biophys Acta Mol Basis Dis. 2018.
Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. N Engl J Med. 2016;374(1):43-53.
Cancer Tissue Procoagulant Mechanisms and the Hypercoagulable State of Patients with Cancer. Semin Thromb Hemost. 2015.
.